CBER seeks steady footing under new FDA leadership
Under acting director Karim Mikhail, the FDA’s Center for Biologics Evaluation and Research is trying to move past a turbulent period by holding adviser meetings and showing flexibility in accepting drug submissions, signaling a return to a more normal operating stance after Vinay Prasad's controversial tenure.